drugset
drugset / Trial / NCT02711345

A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers.

NCT02711345 ↗

Phase 1 Terminated 65 enrolled Novartis Pharmaceuticals
Non-randomizedParallel-groupOpen-labelTreatment

Summary

A phase I study of LTT462 in patients with advanced solid tumors that harbor MAPK pathway alterations.

Timeline

Start
2016-04-15
Primary completion
2018-11-21
Completion
2018-11-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Rineterkib Small molecule — Oral

Indications

melanoma non-small cell lung carcinoma ovarian neoplasm